

Longbow invests in Biotronics 3D

London, 30th October

Longbow Capital, the specialist healthcare investor, today announces that it has completed an investment in medical imaging software company, Biotronics 3D.

Biotronics 3D operates at the point of a step change in the use of medical images. Once the exclusive domain of radiologists, advanced medical image analysis and visualisation can now be accessed by any doctor at any time within the healthcare enterprise. Biotronics 3D's innovative software offers more effective diagnosis at the point of care and better management of surgery and treatments.

London headquartered Biotronics 3D will use the Longbow investment (amount undisclosed) to increase its product portfolio and grow its global market share.

Haralambos Hatzakis, CEO of Biotronics 3D, said:

“Longbow’s understanding of healthcare markets makes them stand out as a partner and investor. We are at an exciting stage of our development as our lead product has gained a strong foothold with international customers. The Longbow investment will now allow us to expand more rapidly. The democratisation of medical imaging is speeding up and Biotronics 3D intends to be a key global player in that process.”

Edward Rudd, Longbow Capital partner, added:

“The global market for medical imaging is approaching \$3 billion*, with an annual growth rate of 15%. The increasing sophistication of imaging hardware requires innovative software to ensure that medical practitioners get the best from their investment. Biotronics 3D has an excellent suite of products that is expected to deliver outstanding returns. Longbow believes that the management team has already made excellent progress, and the investment will allow it to take full advantage of the opportunity.”

Biotronic 3D’s lead suite of products, 3Dnet, has received FDA 501k clearance and is CE marked. The product portfolio includes applications for: 3D diagnostics, virtual colonoscopy, CT angiography, CT perfusion, DCE-MRI perfusion, DCE-MRI breast analysis, and PET / CT. The company’s customer base extends across the USA, Japan, Europe and the UK.

*Frost and Sullivan report 2007

- ENDS -

For more information and pictures please contact:

The Broadcast PR Business: Matthew Locke and Heather Fearfield 020 7469 4036

Longbow Capital: Edward Rudd and Nicola Robson 020 7332 0320

Biotronics 3D: Haralambos Hatzakis 020 7093 0903

About Longbow

Established in 2004 Longbow Capital LLP is a leading specialist in unquoted investments. Its purpose is to bring to early stage unquoted companies the management skills and capital required in order to build successful businesses that can generate significant returns for investors over a 3 to 5 year period.

Longbow manages more than £50 million invested across 36 companies, having added 10 new investments with more than £23 million since its formation.

Longbow seeks to invest in companies looking for development capital with excellent growth prospects as well as the core of a strong management team. It actively searches for investment opportunities offering new and innovative proprietary technologies with wide ranging applications, scalability and, as a result, offers considerable market potential. Longbow tends to focus on a range of areas across personal healthcare and the life sciences.

www.longbow.co.uk